Senti Bio reports additional data from Phase 1 trial of SENTI-202

Senti Bio (SNTI)sciences reported additional positive preliminary data from a Phase 1 clinical trial of SENTI-202, a potential first-in-class off-the-shelf Logic Gated selective CD33 OR FLT3 NOT EMCN chimeric antigen receptor natural killer investigational cell therapy, for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia. SENTI-202 Clinical Results Summary: As presented at AACR, 9 patients with relapsed or refractory AML have been treated with various doses of SENTI-202 in the dose finding part of the study and 7 were evaluable for overall response at the data cut-off. SENTI-202 was well-tolerated with no dose limiting toxicities and a maximum tolerated dose was not reached. The preliminary recommended Phase 2 dose was identified based on the totality of clinical data, including efficacy, as 1.5 x 109 CAR NK cells administered on Days 0,7,14 in 28-day Cycles following lymphodepleting chemotherapy. 2 of 3 patients in the preliminary RP2D cohort achieved a composite Complete Remission; 5 of the 7 best overall response evaluable patients achieved an ORR outcome and 4 of the 7 achieved cCR. All cCR patients continue in remission with the longest follow up being 8+ months, and 3 patients received a bone marrow transplant after treatment with SENTI-202. SENTI-202 treatment decreased AML blasts and leukemia stem cell frequencies and maintained healthy hematopoietic stem and progenitor cell frequencies in patients achieving cCR, consistent with the SENTI-202 Logic Gated gene circuit’s designed mechanism of action. SENTI-202 is generally well tolerated with an adverse event profile that is consistent with other investigational NK cell therapies and patients with underlying AML receiving lymphodepleting chemotherapy.